News | June 01, 2021
Marksans Pharma Q4 FY21 profit up 86%
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
The government has taken all the effective measures to make healthcare affordable
The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
Subscribe To Our Newsletter & Stay Updated
